NEW YORK–(BUSINESS THREAD)–Schrödinger, Inc. (Nasdaq: SDGR), the physics-based software platform transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as Chief Financial Officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger’s CFO, he will lead all aspects of the company’s financial operations and investor relations and corporate affairs activities. He will also oversee the business development and strategic planning of the company’s pharmaceutical and biopharmaceutical partnerships.
“Geoff is a proven leader in the biopharmaceutical and investment industries and has been one of the most respected analysts covering biopharmaceuticals,” said Ramy Farid, Ph.D., Schrödinger’s CEO. “His deep expertise in capital allocation and corporate strategy will play a key role in driving the company’s anticipated growth.”
“After more than 30 years of investment, Schrödinger’s physics-based drug discovery platform has been widely validated and is the leading technology for predictive modeling and drug design in biopharmaceuticals,” said Dr. Porges “The company’s balance sheet and revenue outlook are very strong and there are many opportunities to expand the company’s current portfolio of internal and collaborative programs and software partnerships. I am excited to contribute to the next chapter in Schrödinger’s remarkable story.”
Dr. Porges joins Schrödinger from SVB Securities, where he was most recently vice president. From 2015 to 2022, Dr. Porges was Senior Managing Director, Director of Therapeutics Research and Senior Research Analyst at SVB Securities and Leerink prior to its acquisition by SVB Securities. In this role, he led Leerink/SVB’s therapeutics research team and personally provided research coverage for established and emerging diversified biopharmaceutical companies. Prior to joining SVB Securities, he was a biotechnology research analyst at Alliance Bernstein for 13 years. Earlier in his career, he held executive positions at BTG plc and Merck, including leading the commercialization of Merck’s human vaccines. Dr. Porges received his medical degree from the University of Sydney and trained in internal and pediatric medicine in Australia. He also graduated from Harvard Business School, where he was a Baker Scholar.
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables the discovery of new, high-quality molecules for drug development and materials applications faster and at a lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of new therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has more than 700 employees and works with customers and partners in more than 70 countries. For more information, visit www.schrodinger.com follow us at LinkedIn i Twitteror visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, our expectations regarding the speed and capability of our computing platform, our anticipated growth, opportunities to expand our current portfolio of collaborative and in-house drug discovery programs, and our revenue prospects. Statements that include words such as “goal”, “anticipate”, “believe”, “contemplate”, “continue”, “could”, “estimate”, “expect”, “goal”, “attempt”, “could” ” “potential,” “plan,” “potential,” “prediction,” “project,” “should,” “goal,” “will,” “could,” and forward-looking statements are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on information currently available to us and assumptions we have made.Actual results may differ materially from those described in the forward-looking statements and are subject to to a variety of assumptions, uncertainties, risks and factors beyond our control, including demand for our software solutions, our ability to further develop our computing platform, our reliance on external infrastructure providers base cloud data to host our software solutions, our reliance on our third-party drug discovery collaborators, the ability to retain and hire key personnel, and the ongoing direct and indirect impacts of COVID-19. pandemic on our business and other risks detailed under the heading “Risk Factors” and elsewhere in our filings and reports with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q filed with the Commission of Securities and Exchange on August 4, 2022, as well as future presentations and reports by us. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we have no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.